MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.470
+0.030
+1.23%
Closed 16:00 05/22 EDT
OPEN
2.490
PREV CLOSE
2.440
HIGH
2.500
LOW
2.360
VOLUME
33.42K
TURNOVER
--
52 WEEK HIGH
4.180
52 WEEK LOW
1.530
MARKET CAP
76.24M
P/E (TTM)
-1.7091
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OTIC stock price target is 7.60 with a high estimate of 10.00 and a low estimate of 3.000.

EPS

OTIC News

More
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
GlobeNewswire · 05/12 13:00
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/07 12:30
Otonomy Q4 EPS $(0.360) Beats $(0.440) Estimate, Sales $93.000K Beat $50.000K Estimate
Otonomy (NASDAQ:OTIC) reported quarterly losses of $(0.360) per share which beat the analyst consensus estimate of $(0.440) by 18.18 percent. This is a 14.29 percent increase over losses of $(0.420) per share from the
Benzinga · 05/07 12:16
Edited Transcript of OTIC earnings conference call or presentation 27-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents · 03/26 20:03
Stocks To Watch: 0% To The Rescue?
Seeking Alpha - Article · 03/14 12:49
Easy Come, Easy Go: How Otonomy (NASDAQ:OTIC) Shareholders Got Unlucky And Saw 91% Of Their Cash Evaporate
Simply Wall St. · 03/09 20:53
Otonomy, Inc. 2019 Q4 - Results - Earnings Call Presentation
Seeking Alpha - Article · 03/02 20:50
Otonomy EPS beats by $0.08, beats on revenue
seekingalpha · 02/28 02:39

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About OTIC

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
More

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.